Trial Profile
Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Chronic lymphocytic leukaemia vaccine (Primary) ; Lenalidomide (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Pharmacodynamics
- Acronyms TAIL
- 05 Feb 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 13 Mar 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
- 06 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.